• 1
    Bajorin DF. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol 2001; 19(18 Suppl ): 17S20S.
  • 2
    Gribben JG. Monitoring disease in lymphoma and CLL patients using molecular techniques. Best Pract Res Clin Haematol 2002; 15: 17995.
  • 3
    Cheung IY, Cheung NK, Ghossein RA, Satagopan JM, Bhattacharya S, Coit DG. Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study. Clin Cancer Res 1999; 5: 20427.
  • 4
    Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 2001; 61: 884550.
  • 5
    Wu XR, Manabe M, Yu J, Sun TT. Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem 1990; 265: 191709.
  • 6
    Wu XR, Lin JH, Walz T, Haner M, Yu J, Aebi U, Sun TT. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 1994; 269: 1371624.
  • 7
    Kachar B, Liang F, Lins U, Ding M, Wu XR, Stoffler D, Aebi U, Sun TT. Three-dimensional analysis of the 16 nm urothelial plaque particle: luminal surface exposure, preferential head-to-head interaction, and hinge formation. J Mol Biol 1999; 285: 595608.
  • 8
    Wu XR, Medina JJ, Sun TT. Selective interactions of UPIa and UPIb, two members of the transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells. J Biol Chem 1995; 270: 297529.
  • 9
    Walz T, Haner M, Wu XR, Henn C, Engel A, Sun TT, Aebi U. Towards the molecular architecture of the asymmetric unit membrane of the mammalian urinary bladder epithelium: a closed “twisted ribbon” structure. J Mol Biol 1995; 248: 887900.
  • 10
    Liang FX, Riedel I, Deng FM, Zhou G, Xu C, Wu XR, Kong XP, Moll R, Sun TT. Organization of uroplakin subunits: transmembrane topology, pair formation and plaque composition. Biochem J 2001; 355: 138.
  • 11
    Tu L, Sun TT, Kreibich G. Specific heterodimer formation is a prerequisite for uroplakins to exit from the endoplasmic reticulum. Mol Biol Cell 2002; 13: 422130.
  • 12
    Sun TT, Zhao H, Provet J, Aebi U, Wu XR. Formation of asymmetric unit membrane during urothelial differentiation. Mol Biol Rep 1996; 23: 311.
  • 13
    Sun TT, Liang FX, Wu XR. Uroplakins as markers of urothelial differentiation. Adv Exp Med Biol 1999; 462: 718.
  • 14
    Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol 1999; 155: 104750.
  • 15
    Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, Okada Y. High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res 2002; 93: 52331.
  • 16
    Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, Poulsom R, Selby P, Southgate J. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 2003; 199: 419.
  • 17
    Li SM, Zhang ZT, Chan S, McLenan O, Dixon C, Taneja S, Lepor H, Sun TT, Wu XR. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol 1999; 162: 9315.
  • 18
    Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999; 83: 498503.
  • 19
    Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 195762.
  • 20
    Herr H, Shipley WU, Bajorin DF. Cancer of the bladder. In: De VitaVTJ, HellmanS, RosenbergSA, eds. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001: 1396418.
  • 21
    Yuasa T, Yoshiki T, Tanaka T, Kim CJ, Isono T, Okada Y. Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. Jpn J Cancer Res 1998; 89: 87982.
  • 22
    Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol 1999; 6: 28692.
  • 23
    Gazzaniga P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, Gianni W, Gallucci M, Frati L, Agliano AM. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 2001; 7: 57783.
  • 24
    Osman I, Kang M, Lee A, Chang C, David DA, Mitra N, Wu XR, Sun TT, Bajorin DF. Clinical relevance of detection of uroplakins (UP) and epidermal growth factor receptor (EGFR)–circulating cells in bladder cancer patients. Proceedings of the 94th Meeting of the American Association for Cancer Research (AACR). 2003. 567. Abstract 2493.
  • 25
    Dodd PM, McCaffrey JA, Mazumdar M, Icasiano E, Higgins G, Herr H, Bajorin DF. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Invest New Drugs 2000; 18: 24751.
  • 26
    Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001; 137: 32530.
  • 27
    Blythe C, Still H. Binomial confidence intervals. J Am Statist Assoc 1983; 78: 10816.
  • 28
    Casella G. Refining binomial confidence intervals. Can J Statist 1986; 14: 11329.
  • 29
    Lu JJ, Kakehi Y, Takahashi T, Wu XX, Yuasa T, Yoshiki T, Okada Y, Terachi T, Ogawa O. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res 2000; 6: 316671.
  • 30
    Faillot T, Magdelenat H, Mady E, Stasiecki P, Fohanno D, Gropp P, Poisson M, Delattre JY. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996; 39: 47883.
  • 31
    Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 22835.
  • 32
    Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994; 12: 7309.
  • 33
    Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29(Suppl 4): 2736.